Drug Development Of The Drug Imatinib - 1050 Words

TRM6002 Essay 2 – Drug Development State what the target for the drug imatinib is, and why that target was a good choice for a drug discovery project. Summary/Abstract: Until the 1990’s, drug discovery relied on forward pharmacology where trial and error produced medications that were usually involved in changing DNA synthesis and/or cell division. These medications were efficacious, but had issues with systemic toxicities due to their non-selectivity of diseased cells or disease causing proteins. With the discovery of specific genetic changes that occur in Chronic Myeloid Leukemia, a haematological malignancy, a target was identified which was only seen in diseased cells; thus, rational drug design came about. Imatinib is the first medication of rational drug design with action only in diseased cells. Introduction: Historically, drug discovery projects were aimed at developing drugs that were involved in changing DNA synthesis and/or cell division. These medications included alkylating agents which were very effective but due to the large range of non targeted action within the body, had multiple side effects and toxicities. Since the discovery of specific and varied genetic changes that can occur within cancerous cells, the approach to drug development has changed significantly. Imatinib was one of the first drugs developed where its site of action was only on diseased but not on non-diseased cells. Discussion: Drug discovery programs start when there is aShow MoreRelatedChronic Myeloid Leukemia1139 Words   |  5 PagesRegarding our recent inquiry as to the viability of an Abl-Bcr inhibitor and the marketability thereof, it is of prudent management to discern the separation between our drug candidate and those drugs currently existing in the market, and evaluating the ease of development as well as long-term payoffs of said inhibitor. First, however, an introduction to chronic myeloid leukemia, its symptoms and diagnoses, as well as current treatments, is in order. In better understanding the disease, we can moreRead MoreOrphan Drug Report627 Words   |  3 PagesOrphan Drug Report An orphan drug is a drug designed to treat a rare disease or condition. For a drug to qualify for orphan status both the drug and disease or condition must meet certain criteria specified in the Orphan Drug Act (ODA). This designation would qualify the sponsor of the drug for developmental incentives which includes waiving of regulator fees, faster or simpler clinical trial and approval process, tax credit or grants to offset research and development, and a period of marketingRead MoreAnilinoquinazoline Mechans Of Egfr918 Words   |  4 Pagessignificantly with increased angiogenesis with poor prognosis in NSCLC (Shikada et al., 2005; Kojima et al., 2005). Initial studies show that the combination of bevacizumab and chemotherapy increase the overall survival of advanced colorectal cancer. The drug development strategies added small molecule tyrosine kinase inhibitors for the antiangiogenesis. One preclinical study identified that the combination of bevacizumab and the anti-EGFR TKI Erlotinib are inhibit the receptor like VEGFR and EGFR pathways inRead MorePrice Matter At Customers : Drugs And Treatment For Chronic Myelogenous Leukemia ( Cml )845 Words   |  4 Pagesaffordability of their treatments. For some of the newest treatments on the market, drug prices, and subsequently patient costs, have reached unsustainably high levels. There is no denying that drug development has improved the lives of patients. â€Å"Rational drug design†, the process of developing medications based on the identification of a specific biological target, has produced promising new medications. For instance, Gleevec (imatinib) is a treatment for Chronic Myelogenous Leukemia (CML). In contrast toRead MoreEssay On Sunitinib1480 Words   |  6 Pagesstable disease for at least 12 weeks in 17 % of DTC and 38 % in MTC patients [18]. Imatinib is a TKI that garnered much attention for its highly favorable effect on chronic myeloid leukemia and has inhibitory action against PDGFR-a and PDGFR-b, c-KIT and RET. It has been shown to reduce RET-mediated cell growth of MTC cells [19]. It was investigated in two trials: phase I in which MTC patients treated with imatinib combined with dacarbazine and capecitabine did not report objective responses and phaseRead MoreAdvances in the Pharmaceutical Industry571 Words   |  2 Pagesadvances in the pharmaceutical industry increase as well. While most companies use the mentality of screening drugs that show the most binding affinity or particularity of drug applicants to a single defined target, this is not always the best way of doing things. Many off target activities or multi-targeted particularities have been successful in targeted therapeutics. For example, Imatinib marketed by Novartis and Sorafenib co-developed and co-marketed by Bayer and Onyx Pharmaceuticals and NexavarRead MoreThe Impact Of Traditional Chemotherapeutic Agents On Patients2189 Words   |  9 PagesIn contrast to a decade ago, we’ve seen an explosion of new drugs and virtually all of these drugs are targeted therapies. The substantial increase in the transition of FDA approvals from standard chemotherapeutics to targeted therapies is also equally astounding (Martino et al., 2015). The traditional chemotherapeutic agents are simply not being developed with the same frequency by drug companies any more. While chemotherapeutics have had a real impact and in some diseases a dramatic impact, forRead MoreWhat Would I Do If My Friend Had Leukemia?2592 Words   |  11 Pageskinase. Drugs known as tyrosine kinase inhibitors (TKIs) that target BCR-ABL are the standard treatment for CML. These drugs include Imatinib, Dasatinib, Nilotinib, Bosutinib, and Ponatinib. All of these drugs can have serious or even deadly interactions with other drugs, over the counter supplements, and even certain foods (such as grapefruit and pomegranates). The most common method used for treating Chronic Myeloid Leukemia was Interferon-Alpha. This substance reduces growth and development of leukemiaRead MoreChronic Myeloid Leukemia ( Leukemia )1270 Words   |  6 Pagesmany without these risk factors have will develop leukemia. Treatments can include chemotherapy, to kill the mutated cells in the body, radiation therapy, where high beams of energy are used to stop the further growth of malignant cells, and certain drugs that can target specific weaknesses in the cells again slowing and stopping further growth and proliferation. All of these therapies are dependent on the patient, his or her health, the severity of the disease and type of leukemia. Stem cell therapyRead MoreChronic Myelocytic ( Or Myelogenous ) Leukemia ( Cml )1290 Words   |  6 Pagesin DNA that turn on oncogenes (genes that promote cell growth and division) or turn off tumor suppressor cells (genes that slow down cell division or encourage apoptosis). CML is due to the formation of a new oncogene. The process involves the development of abnormal chromosomes, the abnormal chromosome creating a new fusion-gene, and the fusion-gene creating a protein that triggers cell division of diseased blood cells (Mayo Clinic, Hehlmann et al. 2007). During mitotic cell division in the myeloid